HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants
May 02, 2022 07:00 ET
|
HilleVax, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported today...
HilleVax Announces Pricing of Upsized Initial Public Offering
April 28, 2022 21:03 ET
|
HilleVax, Inc.
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...